<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467621</url>
  </required_header>
  <id_info>
    <org_study_id>RH-ITA-006</org_study_id>
    <nct_id>NCT02467621</nct_id>
  </id_info>
  <brief_title>Stress Ulcer Prophylaxis in the Intensive Care Unit</brief_title>
  <acronym>SUP-ICU</acronym>
  <official_title>Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Morten Hylander Møller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Scandinavian Critical Care Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stress ulcer prophylaxis (SUP) is standard of care in the intensive care unit (ICU), however
      the quantity and quality of evidence is low and potential harm has been reported.

      The aim of the SUP-ICU trial is to asses the overall benefits and harms of SUP with proton
      pump inhibitor in adult critically ill patients in the ICU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critically ill patients in the ICU are at risk of stress related gastrointestinal (GI)
      bleeding, and SUP is recommended. However, the quantity and quality of evidence supporting
      SUP is low and has been questioned. Furthermore studies have shown that proton pump
      inhibitors (PPIs) may increase the risk of pneumonia, clostridium difficile infection and
      acute myocardial ischemia. The aim of the SUP-ICU trial is to assess the benefits and harms
      of SUP with PPI in adult critically ill patients in the ICU.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">January 21, 2018</completion_date>
  <primary_completion_date type="Actual">October 22, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Landmark mortality 90-days after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Important GI Bleeding, Pneumonia, Clostridium Difficile Infection or Acute Myocardial Ischemia</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Composite outcome of the number of participants with one or more of the mentioned conditions in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Important GI Bleeding</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Number of participants with one or more episodes of clinically important GI bleeding in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Infectious Adverse Events</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Number of participants with one or more episodes of pneumonia or clostridium difficile infection in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Data for landmark mortality 1 year after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days Alive Without Organ Support</measure>
    <time_frame>Within 90 days</time_frame>
    <description>Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Reactions</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Serious adverse reactions are: anaphylactic reactions, agranulocytosis, pancytopenia, acute hepatic failure, Steven Johnsons Syndrome and toxic epidermal necrolysis, interstitial nephritis and angioedema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Health Economic Analysis</measure>
    <time_frame>90 days</time_frame>
    <description>This has not been completed yet.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3350</enrollment>
  <condition>Gastrointestinal Bleeding</condition>
  <condition>Stress Ulcers</condition>
  <arm_group>
    <arm_group_label>Proton pump inhibitor (PPI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (0.9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
    <arm_group_label>Proton pump inhibitor (PPI)</arm_group_label>
    <other_name>Pantoloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline (0.9%)</intervention_name>
    <description>10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Acute admission to the ICU

          -  Age ≥ 18 years

          -  One or more of the following risk factors:

               -  Shock (continuous infusion with vasopressors or inotropes, systolic blood
                  pressure &lt; 90 mmHg, mean arterial blood pressure &lt; 70 mmHg or lactate &gt; 4 mmol/l)

               -  Acute or chronic intermittent or continuous renal replacement therapy

               -  Invasive mechanical ventilation which is expected to last &gt; 24 hours

               -  Coagulopathy (platelets &lt; 50 x 109/l or international normalized ratio (INR) &gt;
                  1.5 or prothrombin time (PT) &gt; 20 seconds) documented within the last 24 hours

               -  Ongoing treatment with anticoagulant drugs (prophylaxis doses excluded)

               -  History of coagulopathy (platelets &lt; 50 x 109/l or INR &gt; 1.5 or PT &gt; 20 seconds)
                  within 6 months prior to hospital admission

               -  History of chronic liver disease (portal hypertension, cirrhosis proven by
                  biopsy, computed tomography (CT) scan or ultrasound, history of variceal bleeding
                  or hepatic encephalopathy in the past medical history)

        EXCLUSION CRITERIA:

          -  Contraindications to PPI

          -  Ongoing treatment with PPI and/or H2RA on a daily basis

          -  GI bleeding of any origin during current hospital admission

          -  Diagnosed with peptic ulcer during current hospital admission

          -  Organ transplant during current hospital admission

          -  Withdrawal from active therapy or brain death

          -  Fertile woman with positive urine human chorionic gonadotropin (hCG) or plasma-hCG

          -  Consent according to national regulations not obtainable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Hylander Møller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Perner, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Århus University Hospital Nørrebrogade</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Århus University Hospital Skejby</name>
      <address>
        <city>Arhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurointensive Care, Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Copenhagen University Hospital Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Herning Hospital</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hillerød Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hjørring Hospital</name>
      <address>
        <city>Hjørring</city>
        <zip>9800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Holbæk Hospital</name>
      <address>
        <city>Holbæk</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Holstebro Hospital</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Køge University Hospital</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Nykøbing Falster Sygehus</name>
      <address>
        <city>Nykøbing Falster</city>
        <zip>4800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Randers Hospital</name>
      <address>
        <city>Randers</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Heerlen Hospital</name>
      <address>
        <city>Heerlen</city>
        <zip>6419</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Bergen University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Basel University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Krag M, Perner A, Wetterslev J, Wise MP, Hylander Møller M. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014 Jan;40(1):11-22. doi: 10.1007/s00134-013-3125-3. Epub 2013 Oct 19. Review.</citation>
    <PMID>24141808</PMID>
  </reference>
  <reference>
    <citation>Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttormsen AB, Moller AD, Møller MH; SUP-ICU co-authors. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med. 2015 May;41(5):833-45. doi: 10.1007/s00134-015-3725-1. Epub 2015 Apr 10.</citation>
    <PMID>25860444</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <results_first_submitted>October 29, 2018</results_first_submitted>
  <results_first_submitted_qc>March 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2019</results_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Scandinavian Critical Care Trials Group</investigator_affiliation>
    <investigator_full_name>Dr. Morten Hylander Møller</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Stress ulcer prophylaxis</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Clostridium difficile infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02467621/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Proton Pump Inhibitor (PPI)</title>
          <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1645"/>
                <participants group_id="P2" count="1653"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1644"/>
                <participants group_id="P2" count="1647"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Proton Pump Inhibitor (PPI)</title>
          <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1644"/>
            <count group_id="B2" value="1647"/>
            <count group_id="B3" value="3291"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="56" upper_limit="75"/>
                    <measurement group_id="B2" value="67" lower_limit="55" upper_limit="75"/>
                    <measurement group_id="B3" value="67" lower_limit="55" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="605"/>
                    <measurement group_id="B2" value="580"/>
                    <measurement group_id="B3" value="1185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1039"/>
                    <measurement group_id="B2" value="1067"/>
                    <measurement group_id="B3" value="2106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1644"/>
                    <measurement group_id="B2" value="1647"/>
                    <measurement group_id="B3" value="3291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1061"/>
                    <measurement group_id="B2" value="1064"/>
                    <measurement group_id="B3" value="2125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mortality</title>
        <description>Landmark mortality 90-days after randomization</description>
        <time_frame>90 days</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitor (PPI)</title>
            <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Landmark mortality 90-days after randomization</description>
          <population>Intention-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1642"/>
                <count group_id="O2" value="1640"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="510"/>
                    <measurement group_id="O2" value="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Important GI Bleeding, Pneumonia, Clostridium Difficile Infection or Acute Myocardial Ischemia</title>
        <description>Composite outcome of the number of participants with one or more of the mentioned conditions in the ICU</description>
        <time_frame>Until ICU discharge, maximum 90 days</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitor (PPI)</title>
            <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Important GI Bleeding, Pneumonia, Clostridium Difficile Infection or Acute Myocardial Ischemia</title>
          <description>Composite outcome of the number of participants with one or more of the mentioned conditions in the ICU</description>
          <population>Intention-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1644"/>
                <count group_id="O2" value="1647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360"/>
                    <measurement group_id="O2" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Important GI Bleeding</title>
        <description>Number of participants with one or more episodes of clinically important GI bleeding in the ICU</description>
        <time_frame>Until ICU discharge, maximum 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitor (PPI)</title>
            <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Important GI Bleeding</title>
          <description>Number of participants with one or more episodes of clinically important GI bleeding in the ICU</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1644"/>
                <count group_id="O2" value="1647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Infectious Adverse Events</title>
        <description>Number of participants with one or more episodes of pneumonia or clostridium difficile infection in the ICU</description>
        <time_frame>Until ICU discharge, maximum 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitor (PPI)</title>
            <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Infectious Adverse Events</title>
          <description>Number of participants with one or more episodes of pneumonia or clostridium difficile infection in the ICU</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1644"/>
                <count group_id="O2" value="1647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Data for landmark mortality 1 year after randomization.</description>
        <time_frame>1 year</time_frame>
        <population>Twenty-one patients were lost to follow-up, as compared to the primary outcome (90-day mortality): 7 patients in the PPI arm and 14 patients in the placebo arm</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitor (PPI)</title>
            <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Data for landmark mortality 1 year after randomization.</description>
          <population>Twenty-one patients were lost to follow-up, as compared to the primary outcome (90-day mortality): 7 patients in the PPI arm and 14 patients in the placebo arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1635"/>
                <count group_id="O2" value="1626"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="610"/>
                    <measurement group_id="O2" value="601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days Alive Without Organ Support</title>
        <description>Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy</description>
        <time_frame>Within 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitor (PPI)</title>
            <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days Alive Without Organ Support</title>
          <description>Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy</description>
          <units>percentage of days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1644"/>
                <count group_id="O2" value="1647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious Adverse Reactions</title>
        <description>Serious adverse reactions are: anaphylactic reactions, agranulocytosis, pancytopenia, acute hepatic failure, Steven Johnsons Syndrome and toxic epidermal necrolysis, interstitial nephritis and angioedema.</description>
        <time_frame>Until ICU discharge, maximum 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitor (PPI)</title>
            <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Reactions</title>
          <description>Serious adverse reactions are: anaphylactic reactions, agranulocytosis, pancytopenia, acute hepatic failure, Steven Johnsons Syndrome and toxic epidermal necrolysis, interstitial nephritis and angioedema.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1644"/>
                <count group_id="O2" value="1647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Health Economic Analysis</title>
        <description>This has not been completed yet.</description>
        <time_frame>90 days</time_frame>
        <posting_date>01/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days (for mortality 1 year)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Proton Pump Inhibitor (PPI)</title>
          <description>Pantoprazole 40 mg
Pantoprazole: 40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>Saline (0.9%)
Saline (0.9%): 10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="610" subjects_at_risk="1635"/>
                <counts group_id="E2" subjects_affected="601" subjects_at_risk="1626"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1644"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1647"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="360" subjects_at_risk="1644"/>
                <counts group_id="E2" subjects_affected="372" subjects_at_risk="1647"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Clinically important events</sub_title>
                <counts group_id="E1" subjects_affected="360" subjects_at_risk="1644"/>
                <counts group_id="E2" subjects_affected="372" subjects_at_risk="1647"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Morten Hylander Møller</name_or_title>
      <organization>Copenhagen University Hospital Rigshospitalet, Dept. of Intensive Care 4131</organization>
      <phone>22555343 ext +45</phone>
      <email>mortenhylander@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

